Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis

Autores
Camacho, María Fernanda; Heller, Paula Graciela; Enrico, Alicia; Moiraghi, Beatriz; Castro Ríos, Miguel; Sakmann, Federico; Bendek, Georgina; Vallejo, Veronica; Varela, Ana; Montivero, Romina; De Luca, Geraldine; Gutierrez, Marina; Flores, Daiana; Pereyra, Patricio; Belli, Carolina Bárbara; Larripa, Irene
Año de publicación
2022
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Myelofibrosis (MF) is characterized by stem cell-derived clonal myeloproliferation, associated with bone marrow fibrosis. Most patients present one driver mutation in JAK2, CALR or MPL genes, which are mutually exclusive. The majority acquire others high molecular risk (HMR) in genes affecting epigenetic regulation (ASXL1 and IDH1/2) and splicing machinery (SRSF2 and U2AF1), that may be combined. The Genetically-Inspired Prognostic Scoring System (GIPSS) includes three genetic risk factors: very high risk (VHR) or unfavorable karyotype, HMR mutations and the absence of type 1/like CALR mutations.Our aim was to analyze the karyotypes, driver and HMR genetic variants according to the GIPPS criteria without other clinical parameters.The cohort included 84 patients (56% females) with MF diagnosed according to the 2016 WHO criteria. Driver mutations were 45% JAK2 (p.V617F), 20% Type 1 CALR (p.L367fs*46), 5% Type 2 CALR (p.K385fs*47), 8% MPL (p.W515L/K) and 21% triple-negatives. Genomic DNA samples were analyzed using allele-specific-primers for IDH1/2 (exon 4), Sanger sequencing for ASXL1 (exon 12-13) and high-resolution melting confirmed by Sanger sequencing for SRSF2 (exon 1) and U2AF1 (exon 2). HMR variants were detected in 32 patients (38%), 7 (8%) of them with ≥2 variants. ASXL1 was characterized by frameshift or nonsense variants (n23) while the remaining by missense changes in IDH1 (n1, p.R132H), IDH2 (n5, p.R140Q), SRSF2 (n7, p.P95H/L) and U2AF1 (n4, p.Q157P/R). Abnormal karyotypes were identified in 10 (12%) patients: 6 VHR and 4 unfavorables.The overall survival was 86 months with a median follow-up of 25 months (1-182). The GIPSS score differentiated: High, Intermediate and Low risk (median survival: non reached vs 86 vs 27 months, respectively, p=0.029). No differences were observed between intermediate findings (Int-1 vs Int-2, p=0,866). Our results support the GIPSS model as a prognostic tool to risk-adapt therapy in our MF population.
Fil: Camacho, María Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Heller, Paula Graciela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Fil: Enrico, Alicia. Hospital Italiano de La Plata; Argentina
Fil: Moiraghi, Beatriz. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
Fil: Castro Ríos, Miguel. Centro Medico San Isidro; Argentina
Fil: Sakmann, Federico. Fundación Para Combatir la Leucemia; Argentina
Fil: Bendek, Georgina. Hospital Italiano; Argentina
Fil: Vallejo, Veronica. Instituto Cardiovascular de Buenos Aires; Argentina
Fil: Varela, Ana. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
Fil: Montivero, Romina. Hospital Privado Universitario de Cordoba.; Argentina
Fil: De Luca, Geraldine. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Fil: Gutierrez, Marina. Stamboulian Servicios de Salud; Argentina
Fil: Flores, Daiana. Stamboulian Servicios de Salud; Argentina
Fil: Pereyra, Patricio. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Larripa, Irene. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual de la Sociedad Argentina de Inmunología & 3er Congreso Franco Argentino de Inmunología y Reunión Anual 2022 de la Sociedad Argentina de Fisiología
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Sociedad Argentina de Inmunología
Sociedad Argentina de Fisiología
Materia
MIELOFIBROSIS
GENOMICA
PRONOSTICO
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/291257
Acceder
id CONICETDig_c9ec9a2ac8732d4f3b32bb1e419cacef
oai_identifier_str oai:ri.conicet.gov.ar:11336/291257
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Analysis of genetic variants according to the GIPSS prognostic model in patients with MyelofibrosisCamacho, María FernandaHeller, Paula GracielaEnrico, AliciaMoiraghi, BeatrizCastro Ríos, MiguelSakmann, FedericoBendek, GeorginaVallejo, VeronicaVarela, AnaMontivero, RominaDe Luca, GeraldineGutierrez, MarinaFlores, DaianaPereyra, PatricioBelli, Carolina BárbaraLarripa, IreneMIELOFIBROSISGENOMICAPRONOSTICOhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Myelofibrosis (MF) is characterized by stem cell-derived clonal myeloproliferation, associated with bone marrow fibrosis. Most patients present one driver mutation in JAK2, CALR or MPL genes, which are mutually exclusive. The majority acquire others high molecular risk (HMR) in genes affecting epigenetic regulation (ASXL1 and IDH1/2) and splicing machinery (SRSF2 and U2AF1), that may be combined. The Genetically-Inspired Prognostic Scoring System (GIPSS) includes three genetic risk factors: very high risk (VHR) or unfavorable karyotype, HMR mutations and the absence of type 1/like CALR mutations.Our aim was to analyze the karyotypes, driver and HMR genetic variants according to the GIPPS criteria without other clinical parameters.The cohort included 84 patients (56% females) with MF diagnosed according to the 2016 WHO criteria. Driver mutations were 45% JAK2 (p.V617F), 20% Type 1 CALR (p.L367fs*46), 5% Type 2 CALR (p.K385fs*47), 8% MPL (p.W515L/K) and 21% triple-negatives. Genomic DNA samples were analyzed using allele-specific-primers for IDH1/2 (exon 4), Sanger sequencing for ASXL1 (exon 12-13) and high-resolution melting confirmed by Sanger sequencing for SRSF2 (exon 1) and U2AF1 (exon 2). HMR variants were detected in 32 patients (38%), 7 (8%) of them with ≥2 variants. ASXL1 was characterized by frameshift or nonsense variants (n23) while the remaining by missense changes in IDH1 (n1, p.R132H), IDH2 (n5, p.R140Q), SRSF2 (n7, p.P95H/L) and U2AF1 (n4, p.Q157P/R). Abnormal karyotypes were identified in 10 (12%) patients: 6 VHR and 4 unfavorables.The overall survival was 86 months with a median follow-up of 25 months (1-182). The GIPSS score differentiated: High, Intermediate and Low risk (median survival: non reached vs 86 vs 27 months, respectively, p=0.029). No differences were observed between intermediate findings (Int-1 vs Int-2, p=0,866). Our results support the GIPSS model as a prognostic tool to risk-adapt therapy in our MF population.Fil: Camacho, María Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Heller, Paula Graciela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaFil: Enrico, Alicia. Hospital Italiano de La Plata; ArgentinaFil: Moiraghi, Beatriz. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; ArgentinaFil: Castro Ríos, Miguel. Centro Medico San Isidro; ArgentinaFil: Sakmann, Federico. Fundación Para Combatir la Leucemia; ArgentinaFil: Bendek, Georgina. Hospital Italiano; ArgentinaFil: Vallejo, Veronica. Instituto Cardiovascular de Buenos Aires; ArgentinaFil: Varela, Ana. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; ArgentinaFil: Montivero, Romina. Hospital Privado Universitario de Cordoba.; ArgentinaFil: De Luca, Geraldine. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; ArgentinaFil: Gutierrez, Marina. Stamboulian Servicios de Salud; ArgentinaFil: Flores, Daiana. Stamboulian Servicios de Salud; ArgentinaFil: Pereyra, Patricio. Hospital Nacional Profesor Alejandro Posadas; ArgentinaFil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Larripa, Irene. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaLXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual de la Sociedad Argentina de Inmunología & 3er Congreso Franco Argentino de Inmunología y Reunión Anual 2022 de la Sociedad Argentina de FisiologíaMar del PlataArgentinaSociedad Argentina de Investigación ClínicaSociedad Argentina de InmunologíaSociedad Argentina de FisiologíaFundación Revista Medicina2022info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/291257Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis; LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual de la Sociedad Argentina de Inmunología & 3er Congreso Franco Argentino de Inmunología y Reunión Anual 2022 de la Sociedad Argentina de Fisiología; Mar del Plata; Argentina; 2022; 134-1341669-9106CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://medicinabuenosaires.com/revistas/vol82-22/s5/1s5.pdfNacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2026-08-25T14:41:47Zoai:ri.conicet.gov.ar:11336/291257instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982026-08-25 14:41:47.3CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis
title Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis
spellingShingle Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis
Camacho, María Fernanda
MIELOFIBROSIS
GENOMICA
PRONOSTICO
title_short Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis
title_full Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis
title_fullStr Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis
title_full_unstemmed Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis
title_sort Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis
dc.creator.none.fl_str_mv Camacho, María Fernanda
Heller, Paula Graciela
Enrico, Alicia
Moiraghi, Beatriz
Castro Ríos, Miguel
Sakmann, Federico
Bendek, Georgina
Vallejo, Veronica
Varela, Ana
Montivero, Romina
De Luca, Geraldine
Gutierrez, Marina
Flores, Daiana
Pereyra, Patricio
Belli, Carolina Bárbara
Larripa, Irene
author Camacho, María Fernanda
author_facet Camacho, María Fernanda
Heller, Paula Graciela
Enrico, Alicia
Moiraghi, Beatriz
Castro Ríos, Miguel
Sakmann, Federico
Bendek, Georgina
Vallejo, Veronica
Varela, Ana
Montivero, Romina
De Luca, Geraldine
Gutierrez, Marina
Flores, Daiana
Pereyra, Patricio
Belli, Carolina Bárbara
Larripa, Irene
author_role author
author2 Heller, Paula Graciela
Enrico, Alicia
Moiraghi, Beatriz
Castro Ríos, Miguel
Sakmann, Federico
Bendek, Georgina
Vallejo, Veronica
Varela, Ana
Montivero, Romina
De Luca, Geraldine
Gutierrez, Marina
Flores, Daiana
Pereyra, Patricio
Belli, Carolina Bárbara
Larripa, Irene
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv MIELOFIBROSIS
GENOMICA
PRONOSTICO
topic MIELOFIBROSIS
GENOMICA
PRONOSTICO
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Myelofibrosis (MF) is characterized by stem cell-derived clonal myeloproliferation, associated with bone marrow fibrosis. Most patients present one driver mutation in JAK2, CALR or MPL genes, which are mutually exclusive. The majority acquire others high molecular risk (HMR) in genes affecting epigenetic regulation (ASXL1 and IDH1/2) and splicing machinery (SRSF2 and U2AF1), that may be combined. The Genetically-Inspired Prognostic Scoring System (GIPSS) includes three genetic risk factors: very high risk (VHR) or unfavorable karyotype, HMR mutations and the absence of type 1/like CALR mutations.Our aim was to analyze the karyotypes, driver and HMR genetic variants according to the GIPPS criteria without other clinical parameters.The cohort included 84 patients (56% females) with MF diagnosed according to the 2016 WHO criteria. Driver mutations were 45% JAK2 (p.V617F), 20% Type 1 CALR (p.L367fs*46), 5% Type 2 CALR (p.K385fs*47), 8% MPL (p.W515L/K) and 21% triple-negatives. Genomic DNA samples were analyzed using allele-specific-primers for IDH1/2 (exon 4), Sanger sequencing for ASXL1 (exon 12-13) and high-resolution melting confirmed by Sanger sequencing for SRSF2 (exon 1) and U2AF1 (exon 2). HMR variants were detected in 32 patients (38%), 7 (8%) of them with ≥2 variants. ASXL1 was characterized by frameshift or nonsense variants (n23) while the remaining by missense changes in IDH1 (n1, p.R132H), IDH2 (n5, p.R140Q), SRSF2 (n7, p.P95H/L) and U2AF1 (n4, p.Q157P/R). Abnormal karyotypes were identified in 10 (12%) patients: 6 VHR and 4 unfavorables.The overall survival was 86 months with a median follow-up of 25 months (1-182). The GIPSS score differentiated: High, Intermediate and Low risk (median survival: non reached vs 86 vs 27 months, respectively, p=0.029). No differences were observed between intermediate findings (Int-1 vs Int-2, p=0,866). Our results support the GIPSS model as a prognostic tool to risk-adapt therapy in our MF population.
Fil: Camacho, María Fernanda. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Heller, Paula Graciela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Médicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Fil: Enrico, Alicia. Hospital Italiano de La Plata; Argentina
Fil: Moiraghi, Beatriz. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
Fil: Castro Ríos, Miguel. Centro Medico San Isidro; Argentina
Fil: Sakmann, Federico. Fundación Para Combatir la Leucemia; Argentina
Fil: Bendek, Georgina. Hospital Italiano; Argentina
Fil: Vallejo, Veronica. Instituto Cardiovascular de Buenos Aires; Argentina
Fil: Varela, Ana. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; Argentina
Fil: Montivero, Romina. Hospital Privado Universitario de Cordoba.; Argentina
Fil: De Luca, Geraldine. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Médicas; Argentina
Fil: Gutierrez, Marina. Stamboulian Servicios de Salud; Argentina
Fil: Flores, Daiana. Stamboulian Servicios de Salud; Argentina
Fil: Pereyra, Patricio. Hospital Nacional Profesor Alejandro Posadas; Argentina
Fil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Larripa, Irene. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual de la Sociedad Argentina de Inmunología & 3er Congreso Franco Argentino de Inmunología y Reunión Anual 2022 de la Sociedad Argentina de Fisiología
Mar del Plata
Argentina
Sociedad Argentina de Investigación Clínica
Sociedad Argentina de Inmunología
Sociedad Argentina de Fisiología
description Myelofibrosis (MF) is characterized by stem cell-derived clonal myeloproliferation, associated with bone marrow fibrosis. Most patients present one driver mutation in JAK2, CALR or MPL genes, which are mutually exclusive. The majority acquire others high molecular risk (HMR) in genes affecting epigenetic regulation (ASXL1 and IDH1/2) and splicing machinery (SRSF2 and U2AF1), that may be combined. The Genetically-Inspired Prognostic Scoring System (GIPSS) includes three genetic risk factors: very high risk (VHR) or unfavorable karyotype, HMR mutations and the absence of type 1/like CALR mutations.Our aim was to analyze the karyotypes, driver and HMR genetic variants according to the GIPPS criteria without other clinical parameters.The cohort included 84 patients (56% females) with MF diagnosed according to the 2016 WHO criteria. Driver mutations were 45% JAK2 (p.V617F), 20% Type 1 CALR (p.L367fs*46), 5% Type 2 CALR (p.K385fs*47), 8% MPL (p.W515L/K) and 21% triple-negatives. Genomic DNA samples were analyzed using allele-specific-primers for IDH1/2 (exon 4), Sanger sequencing for ASXL1 (exon 12-13) and high-resolution melting confirmed by Sanger sequencing for SRSF2 (exon 1) and U2AF1 (exon 2). HMR variants were detected in 32 patients (38%), 7 (8%) of them with ≥2 variants. ASXL1 was characterized by frameshift or nonsense variants (n23) while the remaining by missense changes in IDH1 (n1, p.R132H), IDH2 (n5, p.R140Q), SRSF2 (n7, p.P95H/L) and U2AF1 (n4, p.Q157P/R). Abnormal karyotypes were identified in 10 (12%) patients: 6 VHR and 4 unfavorables.The overall survival was 86 months with a median follow-up of 25 months (1-182). The GIPSS score differentiated: High, Intermediate and Low risk (median survival: non reached vs 86 vs 27 months, respectively, p=0.029). No differences were observed between intermediate findings (Int-1 vs Int-2, p=0,866). Our results support the GIPSS model as a prognostic tool to risk-adapt therapy in our MF population.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/291257
Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis; LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual de la Sociedad Argentina de Inmunología & 3er Congreso Franco Argentino de Inmunología y Reunión Anual 2022 de la Sociedad Argentina de Fisiología; Mar del Plata; Argentina; 2022; 134-134
1669-9106
CONICET Digital
CONICET
url http://hdl.handle.net/11336/291257
identifier_str_mv Analysis of genetic variants according to the GIPSS prognostic model in patients with Myelofibrosis; LXVII Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXX Reunión Anual de la Sociedad Argentina de Inmunología & 3er Congreso Franco Argentino de Inmunología y Reunión Anual 2022 de la Sociedad Argentina de Fisiología; Mar del Plata; Argentina; 2022; 134-134
1669-9106
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://medicinabuenosaires.com/revistas/vol82-22/s5/1s5.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.coverage.none.fl_str_mv Nacional
dc.publisher.none.fl_str_mv Fundación Revista Medicina
publisher.none.fl_str_mv Fundación Revista Medicina
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1874774492449865728
score 13.265058

Publicaciones similares